Pemetrexed Injection, Powder, Lyophilized, For Solution
Product Images NDC 31722-336

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pemetrexed (NDC 31722-336). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pemetrexed100cartonlabel (Pemetrexed100cartonlabel)

Box label for Pemetrexed for Injection, USP 100 mg lyophilized powder for intravenous use. The label indicates it is a single-dose vial containing pemetrexed disodium equivalent to 100 mg pemetrexed. Manufactured by Camber Pharmaceuticals, Inc., with additional manufacturing by Hetero Labs Limited, India. The label cautions that the product is a cytotoxic agent and includes storage and reconstitution instructions along with contact information.*

FDA Label Image

Pemetrexed100viallabel (Pemetrexed100viallabel)

Label for Pemetrexed for Injection, USP 100 mg lyophilized powder for intravenous use by Camber Pharmaceuticals, Inc. The single-dose vial label includes a caution for cytotoxic agent, storage instructions, and manufacturer details. The label features a barcode and contact information for U.S. inquiries.*

FDA Label Image

Pemetrexed500cartonlabel (Pemetrexed500cartonlabel)

Packaging label for Pemetrexed for Injection, USP 500 mg single-dose vial by Camber Pharmaceuticals, Inc. The label indicates the drug is for intravenous use only and contains pemetrexed disodium for injection. Storage and reconstitution instructions, caution for cytotoxic agent, and manufacturing information including U.S. contact number and manufacturer details are included.*

FDA Label Image

Pemetrexed500viallabel (Pemetrexed500viallabel)

Label for Pemetrexed for Injection, USP 500 mg single-dose vial. The powder is Pemetrexed disodium equivalent to 500 mg Pemetrexed with excipients. Label specifies intravenous use only, storage instructions, and includes manufacturer information for Camber Pharmaceuticals, Inc. and Hetero Labs Limited. The label features a barcode and a caution about cytotoxic agent.*

FDA Label Image

Pemetrexedfigure1 (Pemetrexedfigure1)

A Kaplan-Meier survival curve showing overall survival percentage over time in months. The chart compares two treatment arms labeled 'A+P+C' and 'A+C', with 'A+P+C' represented by a solid line showing higher survival percentages over time compared to 'A+C' shown with a dashed line. A table below the graph indicates the number of patients at risk at various time points for each treatment group.*

FDA Label Image

Pemetrexedfigure10 (Pemetrexedfigure10)

FDA Label Image

Pemetrexedfigure2 (Pemetrexedfigure2)

A survival probability curve chart comparing Pemetrexed for Injection plus Cisplatin (AC) versus Gemcitabine plus Cisplatin (GC) over a period of 30 months. The x-axis represents survival time in months, and the y-axis shows survival probability. Additionally, a table below the graph lists the number of patients at risk for each group at various time points.*

FDA Label Image

Pemetrexedfigure3 (Pemetrexedfigure3)

A Kaplan-Meier survival curve graph comparing survival probability over time (in months) between two treatment groups: Pemetrexed for Injection plus Cisplatin (AC) and Gemcitabine plus Cisplatin (GC). The graph includes a risk table showing the number of patients at risk at various time points up to 30 months.*

FDA Label Image

Pemetrexedfigure4 (Pemetrexedfigure4)

A survival curve graph showing survival probability over time (months) for two treatment groups: Pemetrexed for Injection combined with Cisplatin (AC) and Gemcitabine combined with Cisplatin (GC). The x-axis represents survival time in months, and the y-axis represents survival probability. The chart also includes patient counts at risk over time for both AC and GC groups.*

FDA Label Image

Pemetrexedfigure5 (Pemetrexedfigure5)

A survival curve graph comparing survival probability over time in months for Pemetrexed for Injection versus placebo. The y-axis represents survival probability from 0.0 to 1.0, and the x-axis shows survival time from 0 to 42 months. Two lines display survival trends: one solid line for Pemetrexed for Injection and one dotted line for placebo. Patient numbers at risk at various time points are listed for both groups below the graph.*

FDA Label Image

Pemetrexedfigure6 (Pemetrexedfigure6)

A Kaplan-Meier survival curve chart showing survival probability over time in months. It compares patients receiving Pemetrexed for Injection with those given a placebo, with solid and dotted lines respectively. The chart includes a table below indicating the number of patients at risk at various time points for both treatment groups.*

FDA Label Image

Pemetrexedfigure7 (Pemetrexedfigure7)

A survival probability curve comparing Pemetrexed for Injection and placebo over survival time in months. The solid line represents Pemetrexed for Injection, and the dotted line represents placebo. Below the graph, a table lists numbers of patients at risk over time for both groups, showing a decreasing count as months progress up to 42 months.*

FDA Label Image

Pemetrexedfigure8 (Pemetrexedfigure8)

A survival probability graph comparing Pemetrexed for Injection to placebo over a survival time in months. The graph shows survival curves with Pemetrexed for Injection represented by a solid line and placebo by a dotted line. Below the graph is a table listing the number of patients at risk for each group at various time points from 0 to 36 months.*

FDA Label Image

Pemetrexedfigure9 (Pemetrexedfigure9)

A survival curve chart showing survival probability over time in months for two groups: Pemetrexed for Injection combined with Cisplatin and Cisplatin alone. The chart includes the number of patients at risk at various time points for both treatment groups.*

FDA Label Image

Pemetrexedstructure (Pemetrexedstructure)

Chemical structure of pemetrexed disodium, showing the molecular arrangement including a pyrrolopyrimidine ring, benzene ring, amide group, and two sodium carboxylate groups with associated waters of hydration (2.5 molecules).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.